France’s First Ever Hobby Shop Focused on GUNPLA: BANDAI HOBBY STORE
27.7.2020 10:00:00 EEST | Business Wire | Press release
BANDAI S.A.S. (President & CEO: Susumu Hirasawa; Head office: Tour W 102, Terrasse Boieldieu 92085 Paris La Defense cedex France) of the BANDAI NAMCO Group, Manga Story SARL (President & CEO: Patrick Carosella; Head office: 13 Boulevard Voltaire, 75011 Paris, France), and BANDAI SPIRITS CO., LTD. (President & CEO: Yusuke Fukuda; Head office: Minato-ku, Tokyo) will open the BANDAI HOBBY STORE, France's first ever hobby shop centered around GUNPLA, in the central Republic district of Paris, France on July 30, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005200/en/
BANDAI HOBBY STORE interior image. It may differ in part from the actual site. (C)SOTSU・SUNRISE
The aim of the BANDAI HOBBY STORE is to expand the BANDAI SPIRITS plastic model business in Europe by offering Europe's largest selection of GUNPLA. In addition to GUNPLA and GUNDAM-related products from the BANDAI NAMCO Group, the store will also offer many other plastic models, etc. from BANDAI SPIRITS.
The central Republic district where the new store will open is home to multiple shops selling games, anime, and comics, attracting users from all around France. Manga Story, the largest shop in the area, began selling BANDAI plastic models, focused on GUNPLA, around four years ago. Discussions with the president, Mr. Carosella regarding the possibility of opening a shop specializing in plastic models had been ongoing for some time, leading to the opening of this new store in the same area.
With about 200 square meters of space on the main floor and in the basement, the store will carry about 600 different types of plastic models, including both new and conventional products. With the various GUNPLA categories organized by color for ease of understanding, and a workshop area at the back of the store where customers can try assembling the models, everyone from child to adult, beginner to expert, will find a variety of ways to enjoy plastic models, from hands-on experience to purchase.
We will use the opening of this store as an opportunity to explore the possibility of opening multiple stores in the future.
|
Store Overview |
|
|
Name: |
BANDAI HOBBY STORE |
|
Location: |
5 boulevard Voltaire, 75011 Paris, France |
|
Business hours: |
Monday-Saturday 10:00-19:30 Closed Sundays |
|
Store area: |
Approximately 200 m2 |
|
Management: |
Manga Story |
|
Admission: |
Free |
What is "GUNPLA"?
GUNPLA are plastic models based on the GUNDAM series, launched in Japan in July 1980 and celebrating their 40th anniversary this year. So far, over 700 million units have been sold: 525.8 million from the Real series, and 174.4 million from the SD series (as of the end of May 2020), making GUNPLA the biggest hit in the history of plastic models. In recent years, we have been growing our overseas market.
Image download URL: https://bit.ly/ (this URL is valid for 30 days from the date of distribution)
* The information in this press release is current as of July 27, 2020, and is subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005200/en/
Contact information
Press inquiries:
BANDAI S.A.S. Makoto Nishiyama (mnishiyama@bandai.fr)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom